• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: NOVO NORDISK A/S, MEDICAL SYSTEMS NOVOPEN ECHO; INSULIN DELIVERY DEVICE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

NOVO NORDISK A/S, MEDICAL SYSTEMS NOVOPEN ECHO; INSULIN DELIVERY DEVICE Back to Search Results
Model Number N/A
Device Problem Mechanical Problem (1384)
Patient Problems Hyperglycemia (1905); Underdose (2542)
Event Date 10/11/2018
Event Type  Injury  
Event Description
Ketosis increased [ketosis], hyperglycaemia [hyperglycaemia], did not deliver the complete dosage of insulin [incorrect dose administered by device], black piston rod of the pen was not in contact with the orange piston [device issue], pen did not deliver the complete dosage of insulin [device malfunction], hyperglycaemia [hyperglycaemia].Case description: this serious spontaneous case from (b)(6) was reported by a pharmacist as "hyperglycaemia" beginning on (b)(6) 2018, "ketosis increased" beginning on (b)(6) 2018, "hyperglycaemia" with an unspecified onset date, "did not deliver the complete dosage of insulin" with an unspecified onset date, "black piston rod of the pen was not in contact with the orange piston" with an unspecified onset date, "pen did not deliver the complete dosage of insulin" with an unspecified onset date, and concerned a (b)(6) male patient who was treated with novopen echo (insulin delivery device) from unknown start date in (b)(6) 2018 due to "type 1 diabetes mellitus", patient's height, weight and body mass index: not reported.Medical history included type 1 diabetes (since 1988), down's syndrome, hyperthyroidism (basedow's disease), constipation.No allergies.Pre-treatment drugs include lantus, novorapid and tresiba flextouch (until (b)(6) 2018).Concomitant products included: tresiba penfill 100 u/ml (insulin degludec) solution for injection, 100 u/ml, (b)(6) 2018 to unk, movicol /01749801/(macrogol 3350, potassium chloride, sodium bicarbonate, sodium chloride), (b)(6) 2016 to ongoing, fiasp flextouch(insulin aspart) solution for injection, 100 u/ml, umuline rapide (insulin human), (b)(6) 2017 to ongoing.Treatment included: potassium chloride (potassium chloride) + "vitchy" water (non codable).Tresiba was prescribed since (b)(6) 2018 first as prefilled pen, then with cartridge since the end of (b)(6) 2018.Novopen echo was started on an unknown date in (b)(6) 2018.The glycaemia levels were fine (several hyperglycaemias were experienced by the patient on an unknown date but they were usual for this patient).From (b)(6) 2018 to (b)(6) 2018, the patient was with his parents and used a pen from his home.From (b)(6) 2018, the patient was back into the hospital and used a pen from the service with a cartridge mounted several days ago.From (b)(6) 2018 to (b)(6) 2018, the glycaemia levels were systematically high (up to 4.5 g/l).The patient also experienced high ketosis on (b)(6) 2018.The ketone level on (b)(6) 2018 was reported as 2.9mmol/l.The nurse noted that when she unscrewed the pen the black piston rod seemed to have an issue.It might not have been in contact with the orange piston.The nurses thought the pen did not deliver the complete dosage of insulin.A change of insulin therapy protocol was done by stopping tresiba.There was improvement of the glycaemia level following the change of "procotol".The patient went back to the initial protocol on (b)(6) 2018 with a pen brought by the parents.The product was then reintroduced without symptom.Then, he used prefilled pens.After a discussion with the nurses, they did not proceed to purge the pen with 2 units.The patient received a treatment for the event: potassium chloride orally + vichy water (non codable).Batch number was available.Action taken to novopen echo was reported as drug discontinued temporarily.On (b)(6) 2018 the outcome for the event "ketosis increased" was recovered.On (b)(6) 2018 the outcome for the event "hyperglycaemia" was recovered.The outcome for the event "hyperglycaemia" was not reported.The outcome for the event "did not deliver the complete dosage of insulin" was not reported.The outcome for the event "black piston rod of the pen was not in contact with the orange piston" was not reported.The outcome for the event "pen did not deliver the complete dosage of insulin" was not reported.This case was reclassified from a non serious case to a serious case on 02-nov-2018 due to the event of "hyperglycaemia" with seriousness criteria of "medically significant".Reporter comment: the hcps suspected a problem with the device and not the cartridge.The pharmacist thought that the nurses did not perform a flow test.No alternative aetiology.
 
Event Description
Case description: investigation results: name: novopen echo, batch number: gvgh235-7.The device was returned with the cartridge from this case mounted.On receipt there was a gap between piston rod of the device and the rubber piston in the cartridge, the piston rod was fully retracted.If the user attempted to make an air shot or to dose prior to this no insulin would have been dispensed.The user either retracted the piston rod correctly during change of the cartridge, but mounted a partly used cartridge afterwards without ensuring contact between the piston rod and the rubber piston by following the air shot procedure, the user left the needle on the pen between injections, or the user retracted the piston rod between injections.The electronic register was checked.No remarks.Visual and functional examinations were performed.The device was tested with a random cartridge and a novo nordisk needle was mounted.During testing it was possible to deliver preparation from the cartridge.The function of the piston rod is normal.The dose accuracy was measured by weighing.The product was found to be normal.The results were found to comply with specifications.Use a new needle for each injection.The needle should be mounted immediately before the injection.Always remove the used needle immediately after each injection and store the device without a needle attached.Otherwise, temperature fluctuations may cause leakage through the needle, resulting in a space between the rubber piston in the cartridge and the piston rod in the device.Furthermore, clogging of the needle may occur.During examination/test of the product it has not been possible to detect any irregularities.The product was found to be normal.Since last submission, the case has been updated with the following: manufacturing comment has been updated.Investigational result updated.Narrative updated accordingly.Manufacturer's comment: upon investigation of returned novopen echo, there was a gap between piston rod of the device and the rubber piston in the cartridge, the piston rod was fully retracted.If the user attempted to make an air shot or to dose prior to this no insulin would have been dispensed.The device was tested with a new cartridge and to be functioning normally.The gap between the plunger and the piston rod could be the result of the user leaving the needle attached to the pen between injections and not checking the insulin flow before the injection as described in the ifu.This could contribute to the patient experiencing a hyperglycemic related event; however it cannot be ruled out that the cartridge was taken out of the pen and the piston rod returned into dosing mechanism before the sample was returned to novo nordisk for investigation evaluation summary name: novopen echo.Batch number: gvgh235-7.The device was returned with the cartridge from this case mounted.On receipt there was a gap between piston rod of the device and the rubber piston in the cartridge, the piston rod was fully retracted.If the user attempted to make an air shot or to dose prior to this no insulin would have been dispensed.The user either retracted the piston rod correctly during change of the cartridge, but mounted a partly used cartridge afterwards without ensuring contact between the piston rod and the rubber piston by following the air shot procedure, the user left the needle on the pen between injections, or the user retracted the piston rod between injections.The electronic register was checked.No remarks.Visual and functional examinations were performed.The device was tested with a random cartridge and a novo nordisk needle was mounted.During testing it was possible to deliver preparation from the cartridge.The function of the piston rod is normal.The dose accuracy was measured by weighing.The product was found to be normal.The results were found to comply with specifications.Use a new needle for each injection.The needle should be mounted immediately before the injection.Always remove the used needle immediately after each injection and store the device without a needle attached.Otherwise, temperature fluctuations may cause leakage through the needle, resulting in a space between the rubber piston in the cartridge and the piston rod in the device.Furthermore, clogging of the needle may occur.During examination/test of the product it has not been possible to detect any irregularities.The product was found to be normal.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
NOVOPEN ECHO
Type of Device
INSULIN DELIVERY DEVICE
Manufacturer (Section D)
NOVO NORDISK A/S, MEDICAL SYSTEMS
hilleroed,
DA 
MDR Report Key8103139
MDR Text Key128334891
Report Number9681821-2018-00075
Device Sequence Number1
Product Code FMF
Combination Product (y/n)N
PMA/PMN Number
K123766
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup
Report Date 10/22/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Lay User/Patient
Device Expiration Date11/30/2019
Device Model NumberN/A
Device Catalogue Number185459
Device Lot NumberGVGH235-7
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer11/05/2018
Initial Date Manufacturer Received 11/02/2018
Initial Date FDA Received11/26/2018
Supplement Dates Manufacturer Received12/07/2018
Supplement Dates FDA Received01/02/2019
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
1) TRESIBA PENFILL; 2) MOVICOL; 3) FIASP FLEXTOUCH; 4) UMULINE RAPIDE; FIASP FLEXTOUCH; MOVICOL; TRESIBA PENFILL; UMULINE RAPIDE
Patient Outcome(s) Other;
Patient Age31 YR
-
-